Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia

BACKGROUND: Once-monthly paliperidone palmitate (PP1M) is a long-acting injectable antipsychotic that may increase adherence rates, reduce hospitalizations, and lower medical costs compared to oral atypical antipsychotics (OAAs) among schizophrenia patients. However, the impact of PP1M in recently d...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilon, Dominic, Muser, Erik, Lefebvre, Patrick, Kamstra, Rhiannon, Emond, Bruno, Joshi, Kruti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457548/
https://www.ncbi.nlm.nih.gov/pubmed/28576133
http://dx.doi.org/10.1186/s12888-017-1358-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457548/
https://www.ncbi.nlm.nih.gov/pubmed/28576133
http://dx.doi.org/10.1186/s12888-017-1358-3

Ejemplares similares